Suzuki I, Takeyama T, Ohno N, Oikawa S, Sato K, Suzuki Y, Yadomae T
J Pharmacobiodyn. 1987 Feb;10(2):72-7. doi: 10.1248/bpb1978.10.72.
Antitumor activity of grifolan NMF-5N, a beta-1,3-glucan obtained from mycelia of Grifola frondosa, was examined. Grifolan NMF-5N showed antitumor activities in allogeneic and syngeneic murine tumor systems. In the allogeneic tumor system, a potent antitumor activity over 95% was observed against the solid form of sarcoma 180 when grifolan NMF-5N was injected intraperitoneally (i.p.) at 25-200 micrograms/mouse daily for 10 successive days. In the syngeneic tumor systems, significant antitumor activities were observed against Meth A fibrosarcoma and MM 46 carcinoma by injection at 100 micrograms/mouse daily for 5 successive days, especially i.p. injection at day 7-11, when the tumor cells were inoculated subcutaneously (s.c.) on day 0. Moreover, when grifolan NMF-5N was injected i.p. every other week, significant antitumor activity was also observed. In addition, a single treatment with grifolan NMF-5N at 500 micrograms/mouse showed antitumor activities. Grifolan NMF-5N exhibited antitumor activities against these two syngeneic tumors by intraveneous (i.v.) injection. However, a marked inhibitory activity was observed by intratumorous (i.t.) injection against Meth A fibrosarcoma but not against MM46 carcinoma. These results suggest that antitumor activities of grifolan NMF-5N in murine syngeneic tumor systems depend on not only dosage but also injection routes and timing.
对从灰树花菌丝体中获得的β-1,3-葡聚糖——灰树花多糖NMF-5N的抗肿瘤活性进行了研究。灰树花多糖NMF-5N在同种异体和同基因小鼠肿瘤系统中均显示出抗肿瘤活性。在同种异体肿瘤系统中，当以25 - 200微克/小鼠的剂量每日腹腔注射（i.p.）灰树花多糖NMF-5N，连续注射10天时，观察到对实体形式的肉瘤180具有超过95%的强效抗肿瘤活性。在同基因肿瘤系统中，当在第0天皮下接种（s.c.）肿瘤细胞后，以100微克/小鼠的剂量每日注射，连续注射5天，尤其是在第7 - 11天进行腹腔注射时，观察到对Meth A纤维肉瘤和MM 46癌具有显著的抗肿瘤活性。此外，当每隔一周腹腔注射灰树花多糖NMF-5N时，也观察到显著的抗肿瘤活性。另外，以500微克/小鼠的剂量单次注射灰树花多糖NMF-5N也显示出抗肿瘤活性。灰树花多糖NMF-5N通过静脉注射（i.v.）对这两种同基因肿瘤显示出抗肿瘤活性。然而，通过瘤内注射（i.t.）对Meth A纤维肉瘤观察到明显的抑制活性，但对MM46癌则没有。这些结果表明，灰树花多糖NMF-5N在小鼠同基因肿瘤系统中的抗肿瘤活性不仅取决于剂量，还取决于注射途径和时间。
